Cytopiloyne, a polyacetylenic glucoside, prevents type 1 diabetes in nonobese diabetic mice

Journal of Immunology

Volumn 178, Issue 11, 2007, Pages 6984-6993

  Chang, Cicero Lee Tian ^a,c   Chang, Shu Lin ^a,b   Lee, Yi Mei ^a   Chiang, Yi Ming ^a   Chuang, Da Yung ^a,c   Kuo, Hui Kai ^a   Yang, Wen Chin ^a,c  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOPILOYNE; FAS ANTIGEN; FAS LIGAND; GLUCOSE; GLUCOSIDE; INSULIN; POLYACETYLENE DERIVATIVE; TACROLIMUS; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BIDENS PILOSA; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; IMMUNOREGULATION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 34249784226     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.11.6984     Document Type: Article

References (54)

1. Atkinson, M. A., and N. K. Maclaren. 1994. The pathogenesis of insulin-dependent diabetes mellitus. N. Engl. J. Med. 331: 1428-1436.
2. Atkinson, M. A., and G. S. Eisenbarth. 2001. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221-229.
3. Kikutani, H., and S. Makino. 1992. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 51: 285-322.
4. Atkinson, M. A., and E. H. Leiter. 1999. The NOD mouse model of type 1 diabetes: as good as it gets? Nat. Med. 5: 601-604.
5. Chervonsky, A. V., Y. Wang, F. S. Wong, I. Visintin, R. A. Flavell, C. A. Janeway, Jr., and L. A. Matis. 1997. The role of Fas in autoimmune diabetes. Cell 89: 17-24.
6. Green, E. A., and R. A. Flavell. 2000. The temporal importance of TNF-α expression in the development of diabetes. Immunity 12: 459-469.
7. Su, X., Q. Hu, J. M. Kristan, C. Costa, Y. Shen, D. Gero, L. A. Matis, and Y. Wang. 2000. Significant role for Fas in the pathogenesis of autoimmune diabetes. J. Immunol. 164: 2523-2532.
8. O'Reilly, L. A., P. Hutchings, P. Crocker, E. Simpson, T. Lund, D. Kioussis, F. Takei, J. Baird, and A. Cooke. 1991. Characterization of pancreatic islet cell infiltrates in NOD mice: effect of cell transfer and transgene expression. Eur. J. Immunol. 21: 1171-1180.
9. + islet-specific T cell clone. Science 249: 1433-1436.
10. + T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 42: 44-55.
11. Katz, J. D., C. Benoist, and D. Mathis. 1995. T helper cell subsets in insulin-dependent diabetes. Science 268: 1185-1188.
12. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16: 34-38.
13. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383: 787-793.
14. Rengarajan, J., S. J. Szabo, and L. H. Glimcher. 2000. Transcriptional regulation of Th1/Th2 polarization. Immunol. Today 21: 479-483.
15. Rabinovitch, A. 1994. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: therapeutic intervention by immunostimulation? Diabetes 43: 613-621.
16. Rabinovitch, A., and W. L. Suarez-Pinzon. 2003. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev. Endocrine Metab. Disord. 4: 291-299.
17. Serreze, D. V., H. D. Chapman, C. M. Post, E. A. Johnson, W. L. Suarez-Pinzon, and A. Rabinovitch. 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166: 1352-1359.
18. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986.
19. Ramiya, V. K., M. Maraist, K. E. Arfors, D. A. Schatz, A. B. Peck, and J. G. Cornelius. 2000. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat. Med. 6: 278-282.
20. Kurasawa, K., T. Koike, R. Matsumura, K. Takabayashi, H. Tomioka, I. Ito, and S. Yoshida. 1990. The immunosuppressant FK-506 prevents progression of diabetes in non-obese diabetic mice. Clin. Immunol. Immunopathol. 57: 274-279.
21. Harlan, D. M., and M. von Herrath. 2005. Immune intervention with anti-CD3 in diabetes. Nat. Med. 11: 716-718.
22. Koike, T., Y. Itoh, T. Ishii, I. Ito, K. Takabayashi, N. Maruyama, H. Tomioka, and S. Yoshida. 1987. Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 36: 539-541.
23. + T cell subsets are required for the transfer of diabetes in non-obese diabetic mice. J. Immunol. 140: 52-58.
24. Adorini, L., J. C. Guery, and S. Trembleau. 1996. Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? Autoimmunity 23: 53-68.
25. Kroemer, G., F. Hirsch, A. Gonzalez-Garcia, and C. Martinez. 1996. Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Autoimmunity 24: 25-33.
26. Marles, R. J., and N. R. Farnsworth. 1995. Antidiabetic plants and their active constituents. Phytomedicine 2: 137-189.
27. Habeck, M. 2003. Diabetes treatments get sweet help from nature. Nat. Med. 9: 1228.
28. Alarcon-Aguilar, F. J., R. Roman-Ramos, J. L. Flores-Saenz, and F. Aguirre-Garcia. 2002. Investigation on the hypoglycaemic effects of extracts of four Mexican medicinal plants in normal and alloxan-diabetic mice. Phytother. Res. 16: 383-386.
29. Krettli, A. U., V. F. Andrade-Neto, M. G. Brandao, and W. M. Ferrari. 2001. The search for new antimalaria drugs from plants used to treat fever and malaria or plants randomly selected: a review. Mem. Inst. Oswaldo Cruz 96: 1033-1042.
30. Hernandez-Galicia, E., A. Aguilar-Contreras, L. Aguilar-Santamaria, R. Roman-Ramos, A. A. Chavez-Miranda, L. M. Garcia-Vega, J. L. Flores-Saenz, and F. J. Alarcon-Aguilar. 2002. Studies on hypoglycemic activity of Mexican medicinal plants. Proc. West. Pharmacol. Soc. 45: 118-124.
31. Lin, C. C. 1992. Crude drugs used for the treatment of diabetes mellitus in Taiwan. Am. J. Chin. Med. 20: 269-279.
32. Ubillas, R. P., C. D. Mendez, S. D. Jolad, J. Luo, S. R. King, T. J. Carlson, and D. M. Fort. 2000. Antihyperglycemic acetylenic glucosides from Bidens pilosa. Planta Med. 66: 82-83.
33. Chang, S. L., C. L. T. Chang, Y. M. Chiang, R. H. Hsieh, C. R. Tzeng, T. K. Wu, H. K. Sytwu, L. F. Shyur, and W. C. Yang. 2004. Polyacetylenic compounds and butanol fraction from Bidens pilosa can modulate the differentiation of helper T cells and prevent autoimmune diabetes in non-obese diabetic mice. Planta Med. 70: 1045-1051.
34. Chang, C. L. T., H. K. Kuo, S. L. Chang, Y. M. Chiang, T. H. Lee, W. M. Wu, L. F. Shyur, and W. C. Yang. 2005. The distinct effects of a butanol fraction of Bidens pilosa plant extract on the development of Th1-mediated diabetes and Th2-mediated airway inflammation in mice. J. Biomed. Sci. 12: 79-89.
35. Todd, J. A., T. J. Aitman, R. J. Cornall, S. Ghosh, J. R. Hall, C. M. Hearne, A. M. Knight, J. M. Love, M. A. McAleer, J. B. Prins, et al. 1991. Genetic analysis of autoimmune type 1 diabetes mellitus in mice. Nature 351: 542-547.
36. Kai, N., K. Motojima, T. Tsunoda, and T. Kanematsu. 1993. Prevention of insulitis and diabetes in non-obese diabetic mice by administration of FK506. Transplantation 55: 936-940.
37. Yang, W. C., K. A. Ching, C. D. Tsoukas, and L. J. Berg. 2001. Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. J. Immunol. 166: 387-395.
38. Wu, W. M., J. L. Suen, B. F. Lin, and B. L. Chiang. 2000. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology 100: 110-118.
39. Deeg, M. A., R. F. Bowen, M. D. Williams, L. K. Olson, E. A. Kirk, and R. C. LeBoeuf. 2001. Increased expression of GPI-specific phospholipase D in mouse models of type 1 diabetes. Am. J. Physiol. 281: E147-E154.
40. Tisch, R., B. Wang, and D. V. Serreze. 1999. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J. Immunol. 163: 1178-1187.
41. + T cell clones. Semin. Immunol. 5: 421-430.
42. Daaboul, J., and D. Schatz. 2003. Overview of prevention and intervention trials for type 1 diabetes. Rev. Endocrine Metab. Disord. 4: 317-323.
43. Von Boehmer, H. 2004. Type 1 diabetes: focus on prevention. Nat. Med. 10: 783-784.
44. Haberstroh, J., T. Wilhelm, J. Schulte-Monting, H. U. Schorlemmer, and B. U. von Specht. 1995. Prevention of type 1 diabetes in the non-obese diabetic (NOD) mouse with 15-deoxyspergualin (15-DS) or 15-DS + cyclosporin A (CyA). Immunol. Lett. 48: 117-121.
45. Casteels, K. M., C. Mathieu, M. Waer, D. Valckx, L. Overbergh, J. M. Laureys, and R. Bouillon. 1998. Prevention of type 1 diabetes in non-obese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. Endocrinology 139: 95-102.
46. Cox, K. L., L. S. Lawrence-Miyasaki, R. Garcia-Kennedy, E. T. Lennette, O. M. Martinez, S. M. Krams, W. E. Berquist, S. K. So, and C. O. Esquivel. 1995. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59: 524-529.
47. Kirby, B., C. M. Owen, R. W. Blewitt, and V. M. Yates. 2002. Cutaneous T cell lymphoma developing in a patient on cyclosporin therapy. J. Am. Acad. Dermatol. 47: S165-S167.
48. Singer, G. G., and A. K. Abbas. 1994. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1: 365-371.
49. Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351.
50. Sytwu, H. K., R. S. Liblau, and H. O. McDevitt. 1996. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5: 17-30.
51. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert, Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273: 109-112.
52. Griffith, T. S., and T. A. Ferguson. 1997. The role of FasL-induced apoptosis in immune privilege. Immunol. Today 18: 240-244.
53. O'Brien, B. A., Y. Huang, X. Geng, J. P. Dutz, and D. T. Finegood. 2002. Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 51: 2481-2488.
54. O'Brien, B. A., X. Geng, C. H. Orteu, Y. Huang, M. Ghoreishi, Y. Zhang, J. A. Bush, G. Li, D. T. Finegood, and J. P. Dutz. 2006. A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse. J. Autoimmun. 26: 104-115.